Apax Partners Leads Spin-Out of Biomarker Discovery Company Sense Proteomic
News Jun 09, 2008
Sense Proteomic Ltd. has announced its spin out and its creation as a biomarker discovery company. It will now be focusing on using its proprietary protein array platform to discover novel panels of auto-antibody biomarkers in cancer and autoimmune diseases.
Sense Proteomic was previously a subsidiary of the biosciences tools business Procognia Ltd, whose other subsidiary was listed on the Tel-Aviv stock exchange in 2007.
Commenting on the deal, Amos Goren, of Apax, said, “Apax is pleased to be supporting the new management team of Sense Proteomic as they develop this exciting business. It is our belief that over the next few years growth in the diagnostic industry will revolutionize healthcare by enabling earlier and more targeted treatment of disease.”
Rachel Fallon Joint CEO said, “Apax’s support will allow us to accelerate our biomarker programmes to validate the strong data we already have in both autoimmune diseases and cancer. This will allow us to maintain our position as leaders in the field.”
Chris Lyddon, Sense Proteomic’s other Joint CEO, added “I am delighted that Apax has invested in Sense Proteomic, their support endorses both our technical approach and our business model”.
Restoring the ability to walk following spinal cord injury requires neurons in the brain to reestablish communication pathways with neurons in the spinal cord, Mature neurons, however, are unable to regenerate their axons to facilitate this process. New research in mice shows one potential route to overcome this limitation may be by targeting liver kinase B1 (LKB1) protein.
International Conference on Cell and Structural biology
Jul 15 - Jul 16, 2019